Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Screening adults for pre-diabetes and diabetes may be cost-saving.

Chatterjee R, Narayan KM, Lipscomb J, Phillips LS.

Diabetes Care. 2010 Jul;33(7):1484-90. doi: 10.2337/dc10-0054.

2.

Cost-effectiveness of screening strategies for identifying pediatric diabetes mellitus and dysglycemia.

Wu EL, Kazzi NG, Lee JM.

JAMA Pediatr. 2013 Jan;167(1):32-9. doi: 10.1001/jamapediatrics.2013.419.

3.
4.

Screening for type 2 diabetes: literature review and economic modelling.

Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A.

Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125. Review.

5.

Screening for diabetes and prediabetes should be cost-saving in patients at high risk.

Chatterjee R, Narayan KM, Lipscomb J, Jackson SL, Long Q, Zhu M, Phillips LS.

Diabetes Care. 2013 Jul;36(7):1981-7. doi: 10.2337/dc12-1752. Epub 2013 Feb 7.

6.

Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies.

Zhang P, Engelgau MM, Valdez R, Benjamin SM, Cadwell B, Narayan KM.

Diabetes Care. 2003 Sep;26(9):2536-42.

PMID:
12941715
7.

Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000.

Icks A, Haastert B, Gandjour A, John J, Löwel H, Holle R, Giani G, Rathmann W; KORA Study Group.

Diabetes Care. 2004 Sep;27(9):2120-8.

PMID:
15333472
8.

Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis.

Zhang P, Engelgau MM, Valdez R, Cadwell B, Benjamin SM, Narayan KM.

Diabetes Care. 2005 Jun;28(6):1321-5.

PMID:
15920046
9.
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
11.

Screening for type 2 diabetes: a short report for the National Screening Committee.

Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B.

Health Technol Assess. 2013 Aug;17(35):1-90. doi: 10.3310/hta17350. Review.

12.

Screening for type 2 diabetes.

Engelgau MM, Narayan KM, Herman WH.

Diabetes Care. 2000 Oct;23(10):1563-80. Review. Erratum in: Diabetes Care 2000 Dec;23(12):1868-9.

13.

The cost of screening for diabetes and intermediate hyperglycaemia.

Colagiuri S.

Diabetes Res Clin Pract. 2012 Sep;97(3):341-2. doi: 10.1016/j.diabres.2012.05.012. Epub 2012 Jun 9. No abstract available.

PMID:
22682947
14.

Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.

Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Engelgau MM.

Diabetes Care. 2007 Nov;30(11):2874-9. Epub 2007 Aug 13.

PMID:
17698614
15.

Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.

Bertram MY, Lim SS, Barendregt JJ, Vos T.

Diabetologia. 2010 May;53(5):875-81. doi: 10.1007/s00125-010-1661-8. Epub 2010 Feb 5.

PMID:
20135088
16.

The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.

[No authors listed]

JAMA. 1998 Nov 25;280(20):1757-63. Erratum in: JAMA 1999 Jan 27;281(4):325.

PMID:
9842951
17.

The cost of diagnosing Type 2 diabetes mellitus by clinical opportunistic screening in general practice.

Pereira Gray DJ, Evans PH, Wright C, Langley P.

Diabet Med. 2012 Jul;29(7):863-8. doi: 10.1111/j.1464-5491.2012.03607.x.

PMID:
22313143
18.

The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.

Diabetes Prevention Program Research Group.

Diabetes Care. 2012 Apr;35(4):723-30. doi: 10.2337/dc11-1468. Erratum in: Diabetes Care. 2013 Dec;36(12):4173-5.

19.

Screening for HbA1c-defined prediabetes and diabetes in an at-risk greek population: performance comparison of random capillary glucose, the ADA diabetes risk test and skin fluorescence spectroscopy.

Tentolouris N, Lathouris P, Lontou S, Tzemos K, Maynard J.

Diabetes Res Clin Pract. 2013 Apr;100(1):39-45. doi: 10.1016/j.diabres.2013.01.002. Epub 2013 Jan 28.

PMID:
23369230
20.

Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C.

Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN.

Diabetes Care. 2007 May;30(5):1120-4. Epub 2007 Mar 2.

PMID:
17337498
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk